Cambridge-based Qureight raises €8 million Series A to accelerate drug development in lung and heart disease

Published on April 16, 2024

Techbio company Qureight has announced the close of their significantly oversubscribed €8 million Series A round. Hargreave Hale AIM VCT led the round, joined by XTX Ventures, Guinness Ventures, and existing investors including Playfair Capital, Meltwind, Ascension Life Fund and Cambridge Angels. The funds will be used to accelerate their AI-driven product portfolio and expand…

This content is for members only. Visit the site and log in/register to read.

The post Cambridge-based Qureight raises €8 million Series A to accelerate drug development in lung and heart disease appeared first on EU-Startups.

Continue reading on website
Other news

Trump Media stock plummets again

April 15, 2024
Trump Media & Technology Group Corp (TMGT) shares plummeted after the entity filed to the U.S. Securities and Exchange Commission (SEC) to issue 21 million shares. The parent company of...

Get Funded: Accessing Money For Your Business with David Souaid

April 16, 2024
David Souaid is the Chief Revenue Officer and member of the board of directors at Journey Capital (formerly OnDeck Canada,) a leader in online small business lending. Journey Capital offers fast and flexible financing to founders so they can refuel their business. Journey Capital uses technology and also the guidance and advice of real business loan advisors to evaluate the financial needs of entr